Abstract:BACKGROUND:Immunotherapy targeting programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) has been shown to be effective in a variety of malignancies but has poor efficacy in pancreatic ductal adenocarcinoma (PDAC). Studies have shown that PD-L1 expression in tumors is an important indicator of the efficacy of immunotherapy. Tumor cells usually evade chemotherapy and host immune surveillance by epigenetic changes. Protein arginine methylation is a common posttranslational modification. Protein arginine methyltransferase (PRMT) 1 is deregulated in a wide variety of cancer types, whose biological role in tumor immunity is undefined. AIM:To investigate the combined effects and underlying mechanisms of anti-PD-L1 and type I PRMT inhibitor in pancreatic cancer in vivo. METHODS:PT1001B is a novel type I PRMT inhibitor with strong activity and good selectivity. A mouse model of subcutaneous Panc02-derived tumors was used to evaluate drug efficacy, toxic and side effects, and tumor growth in vivo. By flow cytometry, we determined the expression of key immune checkpoint proteins, detected the apoptosis in tumor tissues, and analyzed the immune cells. Immunohistochemistry staining for cellular proliferation-associated nuclear protein Ki67, TUNEL assay, and PRMT1/PD-L1 immunofluorescence were used to elucidate the underlying molecular mechanism of the antitumor effect. RESULTS:Cultured Panc02 cells did not express PD-L1 in vitro, but tumor cells derived from Panc02 transplanted tumors expressed PD-L1. The therapeutic efficacy of anti-PD-L1 mAb was significantly enhanced by the addition of PT1001B as measured by tumor volume (1054.00 ± 61.37 mm3 vs 555.80 ± 74.42 mm3, P < 0.01) and tumor weight (0.83 ± 0.06 g vs 0.38 ± 0.02 g, P < 0.05). PT1001B improved antitumor immunity by inhibiting PD-L1 expression on tumor cells (32.74% ± 5.89% vs 17.95% ± 1.92%, P < 0.05). The combination therapy upregulated tumor-infiltrating CD8+ T lymphocytes (23.75% ± 3.20% vs 73.34% ± 4.35%, P < 0.01) and decreased PD-1+ leukocytes (35.77% ± 3.30% vs 6.48% ± 1.08%, P < 0.001) in tumor tissue compared to the control. In addition, PT1001B amplified the inhibitory effect of anti-PD-L1 on tumor cell proliferation and enhanced the induction of tumor cell apoptosis. PRMT1 downregulation was correlated with PD-L1 downregulation. CONCLUSION:PT1001B enhances antitumor immunity and combining it with anti-PD-L1 checkpoint inhibitors provides a potential strategy to overcome anti-PD-L1 resistance in PDAC.

The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2

Osi-027 Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation and Enhances the Therapeutic Effect of Gemcitabine Both in Vitro and in Vivo

OSI-027 Inhibits the Tumorigenesis of Colon Cancer Through Mediation of C-Myc/foxo3a/puma Axis

OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction.

Effect of ARK5 on the Anti-Tumour Activity of OSI-027 Via Regulation of Epithelial-Mesenchymal Transition in Pancreatic Cancer.

Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics

The Novel Mtorc1/2 Dual Inhibitor Ink-128 Suppresses Survival and Proliferation of Primary and Transformed Human Pancreatic Cancer Cells

Antitumor Effects of Rapamycin in Pancreatic Cancer Cells by Inducing Apoptosis and Autophagy.

Mtorc2 Promotes Pancreatic Cancer Progression and Parp Inhibitor Resistance.

Data from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.

Targeted Inhibition of Mammalian Target of Rapamycin (mtor) Enhances Radiosensitivity in Pancreatic Carcinoma Cells.

Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer

Sirolimus Inhibits Human Pancreatic Carcinoma Cell Proliferation by A Mechanism Linked to the Targeting of Mtor/Hif-1 Alpha/Vegf Signaling

Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

Inhibition of PTP1B Blocks Pancreatic Cancer Progression by Targeting the PKM2/AMPK/mTOC1 Pathway

Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells

Gemcitabine Enhances OSI-027 Cytotoxicity by Upregulation of Mir-663A in Pancreatic Ductal Adenocarcinoma Cells

Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma.

Inhibition of Mtor Suppresses Human Gallbladder Carcinoma Cell Proliferation and Enhances the Cytotoxicity of 5-Fluorouracil by Downregulating MDR1 Expression.